(Q38016794)

English

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

scientific article published on September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Jose Luis Gonzalez Larriba

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Jesus Garcia-donas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Enrique Espinosa

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Icíar García Carbonero

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

María López

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Andrés Meana

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Javier Puente

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Joaquim Bellmunt

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 September 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Cancer and Metastasis Reviews

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

31 Suppl 1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S11-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

https://scigraph.springernature.com/pub.10.1007/s10555-012-9354-z

0 references

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Mechanisms of mTOR inhibitor resistance in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Targeting mTOR in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sequential sorafenib and sunitinib for renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

EORTC-GU group expert opinion on metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9354-Z

21 January 2018

Identifiers

10.1007/S10555-012-9354-Z

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Dimensions Publication ID

0 references

release_dhej2aiizvgpjitgcvhgqfcrmq

1 reference

https://api.fatcat.wiki/v0/release/dhej2aiizvgpjitgcvhgqfcrmq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674353%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38016794&oldid=1835741160"